Gastric Carcinoma Clinical Trial
Official title:
A Phase II Study of Celecoxib/Oxaliplatin/Capecitabine Combination Chemotherapy for Unresectable,Recurrent, or Metastatic Gastric/Gastroesophageal Junction Carcinoma
Gastric cancer is the second most common neoplasm in the world. Early diagnosis and surgical resection improve the survival and the chance of cure. Unfortunately, majority of cases are diagnosed at advanced stage, with only 20% of the patients presenting with localized disease. The five-year survival for gastric cancer of all stages remains at a dismal 8%. Chemotherapy has been used for advanced gastric cancer but with unsatisfactory results. Therefore, new approaches are needed for these patients. Among the newer chemotherapy regimens for advanced gastric cancer include a combination of oral 5-Fluoro-Uracil (FU)-based compound called Capecitabine(Xeloda) and Oxaliplatin. A few phase II studies suggest that the combination regimen is active with overall response rates ranging 30-40%. Several preclinical and clinical studies have shown that the expression of cyclooxygenase enzyme II(COX-2) is upregulated in many pre-neoplastic and neoplastic lesions. Furthermore, there appears to be an association with the overexpression of Cox-2 and the invasiveness of cancer and prognosis. Finally, preclinical and clinical studies suggest selective Cox-2 inhibitors can induce apoptosis in gastric cancer cells and retard tumor progression. Therefore, there is a strong rationale for the combination of a selective Cox-2 inhibitor, Celecoxib, with Capecitabine and Oxaliplatin in a therapeutic phase II trial for patients with advanced or recurrent gastric cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04602026 -
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
|
N/A | |
| Not yet recruiting |
NCT03599778 -
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
| Recruiting |
NCT02617134 -
CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02317471 -
Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03735511 -
A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma
|
||
| Recruiting |
NCT04410302 -
Patient-Derived Xenografts to Reduce Cancer Health Disparities
|
||
| Recruiting |
NCT05596188 -
Anxiety Before Non-cardiac Surgery in Adults
|
||
| Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT01348009 -
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00639522 -
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05811546 -
Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma
|
||
| Recruiting |
NCT05229809 -
Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer
|
Phase 4 | |
| Recruiting |
NCT02409199 -
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00970138 -
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04443036 -
Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma
|
N/A | |
| Active, not recruiting |
NCT04505553 -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
|
Phase 2 | |
| Recruiting |
NCT02839954 -
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
|
Phase 1/Phase 2 | |
| Terminated |
NCT03957096 -
A Safety Study of SGN-CD47M in Patients With Solid Tumors
|
Phase 1 |